Opnurasib for Lung Cancer

(KontRASt-R Trial)

This trial tests opnurasib, a treatment for lung cancer, to determine its continued safety and benefits for participants already using it. The trial includes different groups testing opnurasib alone or in combination with other medications, such as TNO155 and trametinib. It suits those currently enrolled in a specific Novartis study who have taken opnurasib for at least six cycles and are experiencing benefits like reduced disease progression or improved quality of life. As a Phase 1, Phase 2 trial, it aims to understand how the treatment works in people and measure its effectiveness in an initial group.

The trial information does not specify whether you need to stop taking your current medications. It's best to discuss this with the trial team or your doctor.

Previous studies have shown that opnurasib is generally safe. Research indicates that patients with non-small cell lung cancer (NSCLC) and a specific mutation called KRAS G12C tolerate it well. Most reported side effects were mild and manageable.

When combined with TNO155, opnurasib commonly causes swelling, low blood cell counts, and tiredness, but these effects were not severe enough to halt treatment.

The safety profile of opnurasib with trametinib is similar, with mostly mild side effects reported.

When paired with cetuximab, opnurasib has caused some treatment-related side effects, but no severe reactions were observed, though there is a slight risk of liver-related issues.

The combination of opnurasib and tislelizumab also demonstrates a good safety and tolerability profile.

Researchers are excited about opnurasib for lung cancer because it targets a specific mutation in cancer cells that many standard treatments, like chemotherapy and radiation, don't specifically address. Opnurasib acts by inhibiting the KRAS G12C mutation, a notorious driver in many lung cancers, offering a more tailored approach compared to the broader mechanisms of traditional therapies. The trial also explores combinations of opnurasib with other agents like TNO155, trametinib, cetuximab, and tislelizumab, each potentially enhancing its effectiveness by targeting different cancer pathways or boosting the immune response. This multi-faceted strategy could lead to more effective and personalized treatments for lung cancer patients.

Research has shown that opnurasib alone has potential in treating non-small cell lung cancer (NSCLC) with a specific KRAS G12C mutation, with studies finding that 41.7% of patients responded positively to the treatment. In this trial, participants may receive opnurasib alone or in combination with other drugs. When combined with TNO155, 66.7% of patients experienced disease control, and 33.3% showed a positive response. The combination of opnurasib and trametinib resulted in disease control for 83% of patients. Additionally, pairing opnurasib with cetuximab led to a 34% positive response rate and an 85% disease control rate. Finally, combining opnurasib with tislelizumab has shown improved outcomes, with studies indicating significant improvements in survival rates.¹³⁴⁶⁷